ECMO or Tracheostomy with MV >96 Hours DRG - Reimbursement

Summary & Overview

ECMO or Tracheostomy with MV >96 Hours: Inpatient Reimbursement Overview

DRG 003 encompasses extracorporeal membrane oxygenation or tracheostomy with mechanical ventilation greater than 96 hours, or principal diagnoses (except face, mouth, and neck) with major operating room procedures, and represents high-acuity inpatient care. This Diagnosis-Related Group is important for inpatient reimbursement because it captures cases with significant resource intensity that influence Medicare Severity Diagnosis-Related Group payment levels.

ECMO or Tracheostomy with MV >96 Hours or Principal Diagnosis Except Face, Mouth and Neck with Major O.R. ProceduresDRG ECMO or Tracheostomy with MV >96 Hours or Principal Diagnosis Except Face, Mouth and Neck with Major O.R. ProceduresDRG 003Diagnosis-Related GroupInpatient ReimbursementMedicareCritical CareCardiothoracic SurgeryMechanical VentilationIntensive Care

DRG 003 Overview

DRG 003 covers hospitalizations involving extracorporeal membrane oxygenation or tracheostomy with mechanical ventilation beyond 96 hours, or admissions with a principal diagnosis outside the face, mouth, and neck that include major operating room procedures. This Diagnosis-Related Group groups high-acuity surgical and respiratory support cases with substantial resource use. It matters for Medicare payment because it identifies cases with intensive care, prolonged ventilation, and major procedures that drive higher Medicare Severity Diagnosis-Related Group payments. Accurate clinical coding and documentation determine assignment to this Diagnosis-Related Group and therefore affect inpatient reimbursement.

National Payment Rates

Across payers the documented rate range spans from about $370 up to $690K, with the widest spread of roughly $689.6K observed between the lowest and highest reported values; see the table and chart below for payer-level detail. Payer benchmarks include Cigna, Blue Cross Blue Shield, Anthem, and Aetna, with mean values clustering between approximately $170K and $350K. These benchmarks illustrate substantial variation in allowed or negotiated rates across commercial payers.

Mean Rates by Payer — National — DRG 003

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s reported mean payments for DRG 003 range from $330K to $510K across the three payers in the state data. Blue Cross Blue Shield and Anthem are both at $330K, while Cigna stands out at $510K, representing the most notable deviation from the state cluster. This Cigna mean is also higher than many national median benchmarks. See the table and chart below for payer-level detail.

Key Insights for Alaska

Anthem is the highest paying payer in Alaska at a mean of $330K, while BCBS and Anthem share identical reported means; Cigna shows a higher mean at $510K, making Cigna the true highest payer and Anthem/Blue Cross Blue Shield the lowest at $330K.
Alaska’s payer means cluster tightly at $330K for Anthem and BCBS, but Cigna deviates meaningfully above the state cluster at $510K, which is notably higher than typical national medians for comparable payers.

Clinical Trials

Acute organ-support intervention trials: studies assessing new techniques or protocols for extracorporeal membrane oxygenation (ECMO) initiation, cannulation strategies, anticoagulation regimens, or ventilator management bundles in patients requiring ECMO or prolonged mechanical ventilation (>96 hours), including patients with severe respiratory failure, cardiogenic shock, or perioperative needs after major thoracic or cardiac surgery. These trials focus on short-term physiologic endpoints (survival to decannulation or ventilator liberation, bleeding/thrombotic complications, ICU length of stay) and are highly relevant to clinicians managing complex critical care pathways and to payers because changes in complication rates and ICU days materially affect resource utilization and reimbursement under high-cost DRGs.
Comparative effectiveness studies of tracheostomy timing and technique: prospective cohort or randomized studies comparing early versus late tracheostomy, percutaneous versus surgical approaches, and standardized weaning protocols in patients anticipated to require >96 hours of mechanical ventilation or who undergo airway procedures during major operations. These studies evaluate outcomes such as time to liberation from ventilation, incidence of ventilator-associated pneumonia, long-term functional status, and hospital readmissions; they inform best practices for procedural choice and timing that can reduce complications, shorten lengths of stay, and guide payer policies around bundle payments and care pathways.
Post-discharge recovery and long-term outcomes research: longitudinal observational studies and pragmatic trials following survivors of ECMO, prolonged MV, or tracheostomy to assess physical, cognitive, and respiratory recovery, rates of rehospitalization, need for home mechanical ventilation or outpatient therapies, and cost trajectories over 6–24 months. This research addresses rehabilitation needs, discharge planning, and durable resource use—critical for providers designing post-ICU care pathways and for payers estimating long-term costs and evaluating value of early interventions that may reduce downstream utilization.

Autologous Bone Marrow Transplant with CC/MCC: Inpatient Reimbursement Overview

018-CHIMERIC-ANTIGEN-RECEPTOR-CAR-T-CELL-AND-OTHER-IMMUNOTHERAPIES

Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies: Inpatient Reimbursement Overview

013-TRACHEOSTOMY-FOR-FACE-MOUTH-AND-NECK-DIAGNOSES-OR-LARYNGECTOMY-WITHOUT-CC-MCC

Tracheostomy/Laryngectomy without CC/MCC: Inpatient Reimbursement Overview

011-TRACHEOSTOMY-FOR-FACE-MOUTH-AND-NECK-DIAGNOSES-OR-LARYNGECTOMY-WITH-MCC

Tracheostomy/Laryngectomy with MCC: Inpatient Reimbursement Overview

006-LIVER-TRANSPLANT-WITHOUT-MCC

Liver Transplant without Major Complication or Comorbidity: Inpatient Reimbursement Overview

008-SIMULTANEOUS-PANCREAS-AND-KIDNEY-TRANSPLANT

Simultaneous Pancreas and Kidney Transplant: Inpatient Reimbursement Overview

002-HEART-TRANSPLANT-OR-IMPLANT-OF-HEART-ASSIST-SYSTEM-WITHOUT-MCC

Heart Transplant or Implant of Heart Assist System without MCC: Inpatient Reimbursement Overview

012-TRACHEOSTOMY-FOR-FACE-MOUTH-AND-NECK-DIAGNOSES-OR-LARYNGECTOMY-WITH-CC

Tracheostomy and Laryngectomy with CC: Inpatient Reimbursement Overview

019-SIMULTANEOUS-PANCREAS-AND-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS

Simultaneous Pancreas and Kidney Transplant with Hemodialysis: Inpatient Reimbursement Overview

014-ALLOGENEIC-BONE-MARROW-TRANSPLANT

Allogeneic Bone Marrow Transplant: Inpatient Reimbursement Overview

Showing 1–10 of 16

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

ECMO or Tracheostomy with MV >96 Hours: Inpatient Reimbursement Overview

DRG 003 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes